Member Info for AP-Invest

BID is 1.75p ASK is 0.75, spread is 1p (57%) and SP is 0.90

at 0.82p

That is an insane spread.

I wonder if MM's will be triggering stop/losses today.

I'd be very surprised to see this drop anywhere near 0.40p, most likely se drop and then a rise later after stop/losses triggered and panic sellers out.

Can't buy or sell.

InterpidInvestor; can I ask you a question? - In these sorts of scenarios where a company like MTFB go to II for placing and say we need 'X' amount (650k) to keep the lights on as we're likely to be suspended on July 28th for 6 months if there is no deal.

Would it not be favourable for them to say in discussions that they have 'X' candidate lined up for an RTO to get the funds over the line... I mean surely that is a huge risk for II to give away 650k to a company if there was NO RTO CANDIDATE! and potential suspension in two months given the current economic climate...

I suppose what I am indirectly saying is if there was no RTO candidate lined up, why would II invest at 0.40, which would've been higher than the SP when talks went ahead... Lets be honest, these talks would've gone ahead before the price went to above 1p. Most likely these talks went ahead when the price was around 0.20... I couldn't imagine the price going to 1p and then the company saying 'lets call II to get some money and everything going ahead in an hour or two...'

Someone knew something yesterday and leaked info. The funding was secured at 0.40 - price went up to 1.8p, RNS today to confirm. People always know and majority of II who were informed probably traded on that inside information.

The price didn't drop when Hercules received options at 0.42? Why would the price drop down to 0.4 on open or today when the placing will go ahead on 11th May. They represent 25% of available shares, surely the stock would be valued 25% less.

I have a feeling most people will be out within a couple of days... I highly doubt many will wait for the RTO - I'd imagine those who were in back at 10-40p will obviously hold out because they're so far down but most people made a good 100% yesterday. If theres anything similar in the next few days they will be out.

Worse bit about it is my shares are in a LISA. No access until 2056 without taking a penalty.

That is very true but now is the perfect time for small pahrma companies to perform and become noticed. Big pharma have been so focused on maintaining life rather than preventing death for such a long time now, with the likes of diabetes, hypertension etc.

It provides a platform, the fact that the newly appointed CEO yesterday is on with Lemellar and LMS611 and Iclaprim work together is music to my ears. They're both in the cystic fibrosis space, and around 25% of patients with cystic fibrosis have MRSA. Not 100% sure on the link with covid-19 yet, perhaps its due to lung damage and the two medicines augmenting each other or maybe theres more to the picture. Studies have been shown that Iclaprim is a good candidate and FDA have given us details on what we need to do to market the medicine, market ourselves basically and have an RTO. The new appointment of Chris Wardhaugh will help us to market the company as he has been successful in this space before. The placing today raises enough cash to keep the lights on until Feb 2021, isn't great due to further share dilution, but if suspended I am not sure on the legalities regarding raising cash or placing or if they can do so...

I wonder if they actually have someone in talks.

They need to secure the deal before June 28th I think it is? What if they've secured funding because they know they will be suspended in talks after and no way of raising cash... The money raised should last until around Feb 2021 they're saying, which gives them enough time..

Just a thought and a speculative one at that...

50% down on open? This will cross 2p today.

- In addition to the Hercules loan settlement; Hercules have options at 0.42.
- FDA have given us advice on how to market Iclaprim.
- Iclaprim and LMS611 (Lemellar's compund), if you put the both together you have an enhancing effect.

What sort of question is this?

Do you want a biased answer; yes, invest everything you can tomorrow.
Do you want an unbiased answer; yes, invest everything you can tomorrow.

Seriously...

Since then, there was the RNS on 30/09/2020, about the Hercules Loan agreement.

Numerous 'price monitoring' activity and Institutional investors decreasing their holding

Furthermore, please see this video; https://www.youtube.com/watch?v=p3HQzzZQhpI

24th May 2019 - 1:10 This is a video of Graham Lumsden talking about Iclaprim (Motif bio) and LMS611 (Lamellasome) Working together to treat Staphylococcus Aureus pneumonia in cystic fibrosis. Iclaprim already have an 'Orphan status' in USA.

RNS Today (04/04/2020):
Appointment of Chris Wardhaugh is appointed as a Non-Executive Director;
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.

Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.

- 24/10/2019; U.S. Army-funded research project to Evaluate Iclaprim. The Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.

The aerosol technology allows delivery of antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery. The research is being funded through a grant from the U.S. Department of Defense - Congressionally Directed Military Infectious Diseases Research Program to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield. The work will be led by Dr. Daniel Zurawski,

David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible. The data generated from Dr. Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections.”

In March 2020 a paper was released that compared PHASE 3 REVIVE of the safety and efficacy of Iclaprim vs Vancomycin for treatment of acute bacterial skin and skin structure infections.

Results: Results. In REVIVE-1, ECR was 83.5?% with iclaprim versus 79.7?% with vancomycin (treatment difference 3.77%, 95?%?CI -4.50%, 12.04%). In REVIVE-2, ECR was 82.7?% with iclaprim versus 76.3?% with vancomycin (treatment difference 6.38%, 95?%?CI -3.35%, 16.12%). In the pooled dataset, iclaprim had similar ECR rates compared with vancomycin among wound infection patients (83.2?% vs 78.2?%) with a treatment difference of 5.01?% (95?% CI -1.29%, 11.32%). The safety profile was similar in iclaprim- and vancomycin-treated patients, except for a higher incidence of diarrhea with vancomycin (n=17) compared with iclaprim (n=6) and fatigue with iclaprim (n=17) compared with vancomycin (n=8).
Conclusion. Based on early clinical response, iclaprim achieved non-inferiority to vancomycin with a similar safety profile in patients with wound infections suspected or confirmed as caused by Gram-positive pathogens. Iclaprim may be a valuable treatment option for wound infections.

-10/10/2019; As disclosed in the announcement on September 30, 2019, the minutes confirm that a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with HABP, including VABP, along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application for approval by FDA. It would take several years to enrol and complete a HABP/VABP Phase III trial and the cost is expected to be tens of millions of dollars.

The Company continues to believe that the most efficient way to generate future value from iclaprim is for a partner or other entity with a lower cost of capital to complete the HABP/VABP Phase III trial and commercialise the asset globally.

Dr. Graham Lumsden, Chief Executive Officer, said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval. The Company is working hard to find a partner or other entity to complete the HABP/VABP Phase III trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."

Forgot to add this!

Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.

https://www.youtube.com/watch?v=p3HQzzZQhpI

24th May 2019 - 1:10 This is a video of Graham Lumsden talking about Iclaprim (Motif bio) and LMS611 (Lamellasome) Working together to treat Staphylococcus Aureus pneumonia in cystic fibrosis. Iclaprim already have an 'Orphan status' in USA.

RNS Today:
Appointment of Chris Wardhaugh is appointed as a Non-Executive Director;
Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.